Answer
It is unknown whether romiplostim or its metabolites pass into human breast milk; risk to infants cannot be excluded, so a decision about stopping breastfeeding or romiplostim must weigh the benefits to the child and mother.
Sources for this answer
- Nplate 250 micrograms powder and solvent for solution for injectionAmgen Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 21Document updated
Sources checked